it shows that after you get that third immunization, whereas it was, you know, reinstalling 90%, 95% protection versus the previous lineages, it s around 70% to 75% against omicron. still pretty good and much better against hospitalizations. but against symptomatic infections, 70%, 75%. the problem is it s not holding up. it seems to be going down quickly after two or three months, down to maybe 30% to 40% according to imperial college. the idea for the fourth immunization, again, is another way to keep our health care workers in the health care workforce to rebump up their virus neutralizing antibodies. so my recommendation specifically for the health care workers, although israel is extending that not only to health care workers but those individuals either over the age of 60 or 70, and like so many other things, we depend so heavily on israel and the uk for vaccine effectiveness data, and we ll see what happens with that
designers of the patentless vaccine, which has just been granted emergency use authorization in india. we want to talk about that, dr. hotez. that is incredibly significant news. but first i would like to get your reaction to this new johnson & johnson report. well, you know, kaitlan, this was actually always a good vaccine. the j&j vaccine is an outstanding vaccine. if you give it in two doses. i think what s happened here in the united states is there are a lot of circumstances that cause people to lose public confidence in it. i think one was the fact that, you know, we don t most of our vaccine effectiveness data comes from israel and the uk. we re not collecting a lot of effectiveness data in the united states. you would always hear about the pfizer vaccine, mrna, and people would extrapolate to the moderna vaccine. every day i would get emails expecting buyers remorse because
to weigh whether a faction eshould be released to certain populations? does it make sense to just take j&j off the payable? as i sake to say. it doesn t take much even for a good vaccine to be taken off the market because of public perception and it took two fits. one is the fact that almost of our vaccine effectiveness data is coming out of the criminal and the uk and the vaccine is not used in those two din industries from. they haven t happy with had a they got and then the cdc throws
there s a possibility. in fairness to johnson & johnson, for pfizer, we had the data for vaccine effectiveness coming out of israel and the uk. that s what really i think helped push this over the edge with the fda. moderna and johnson & johnson are not used in those countries. we haven t really collected vaccine effectiveness data as much as we would like. it s a good vaccine. but there are deficiency in the packet. there s misunderstanding about the paper that came out yesterday in terms of johnson & johnson as a booster. let me ask you this. there s a report this morning that perhaps you are better off getting another getting one of the mrna vaccines as a booster if you took johnson & johnson. explain why that is. that s exactly what i was referring to. this was a pre-print that came
data, the johnson & johnson vaccine as a two dose vaccine is still very good. how comfortable i know that pfizer, moderna, johnson & johnson have good scientific reputations. that said, how comfortable are you that we are relying on their data sets, their collection of data? shouldn t this be done independently? shouldn t we be asking maybe it s another academic institution, but shouldn t we collect the data on the vaccines that way? typically it would be a combination of the two. there would be independent studies. this is why pfizer had the advantage of the data collected by the ministry of health of israel and israeli scientists. same with the uk. you are right. this has been a problem that we have had with cdc that we have not really collected vaccine effectiveness data here in the u.s. at the level we should have. that s working to the